Clinical Trials
7 trialsNCT06745583 2026-06-03
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Phase 2 Recruiting
NCT05522387 2026-02-27
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Inmune Bio, Inc.
Phase 2 Terminated
NCT05321498 2023-09-28
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
Inmune Bio, Inc.
Phase 2 Withdrawn
NCT02452216 2017-08-31
Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS
Stanford University
Phase EARLY_PHASE1 Completed
NCT01969370 2017-05-03
NCGENES
University of North Carolina, Chapel Hill
Phase NA Completed
NCT02108769 2014-04-09
Yogic Breathing Changes Salivary Components
Medical University of South Carolina
Phase NA Completed
NCT00643890 2012-02-22
Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease
Neurologix, Inc.
Phase 2 Terminated